Collection efficiency on the fenwal CS3000 when using filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) as a peripheral blood stem cell mobilization agent
✍ Scribed by L. Bik To; German R. Stemmelin; David N. Haylock; Joanne L. Bayly; Dawn Thorp; Caroline M. Rawling; Sandra Trimboli; Christopher A. Juttner
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 376 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The collection efficiency (CE) of the Fenwal CS3000 in collecting peripheral blood stem cells during post‐chemotherapy recovery phase ranges from 58% to 73%. Recently filgrastim (recombinant methionyl human granulocyte colony‐stimulating factor [G‐CSF]) has also been shown to be effective as a mobilization agent although mobilization occurs during elevated and not low normal leukocyte counts. We compared the mononuclear cell (MNC) CE and the myeloid progenitor cell (CFU‐GM) CE among 11 patients with G‐CSF mobilization (33 procedures) and 19 patients during recovery following myelosuppression chemotherapy (93 procedures). Pre‐apheresis leukocyte, neutrophil, MNC, and PB CFU‐GM counts were significantly higher in the G‐CSF group, while the granulocyte percentage in the apheresis products was similar in both groups. Both MNC CE (81.8 ± 4.5% vs. 64 ± 2.4%) and CFU‐GM CE (79.5 ± 10.5% vs. 55.8 ± 3.5%) were higher in the G‐CSF group. Only the pre‐apheresis MNC count showed an independently significant correlation for both CE (P <.001). The higher CE in the G‐CSF group can only be partly explained by a rise in MNC count during apheresis. These data suggest that the blood cell separator works better with leukocytosis, and especially with a higher MNC count. The improvement in CE is another benefit of G‐CSF mobilization over chemotherapy mobilization. © 1994 Wiley‐Liss, Inc.